Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
Completed · Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and bexarotene, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Bexarotene may also cause cutaneous T-cell lymphoma cells to look more like normal cells, and to grow and spread more slowly. Giving liposomal doxorubicin followed by bexarotene may be an effective treatment for cutaneous T-cell lymphoma. PURPOSE: This phase II trial is studying how well giving liposomal doxorubicin followed by bexarotene works in treating patients with cutaneous T-cell lymphoma.
Key facts
- Study ID
- NCT00255801
- Run by
- Memorial Sloan Kettering Cancer Center
- People needed
- 37
- Starts
- 2005-11-01
- Expected to finish
- 2017-10-01
- Last updated by the study team
- 2018-08-16
Who can join
Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Hackensack University Medical Center Cancer Center — Hackensack, New Jersey, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- NYU Cancer Institute at New York University Medical Center — New York, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.